Adverum Biotechnologies, INC Form 4 insider transactions
Adverum Biotechnologies, Inc. Director Soo Hong was granted 10,450 stock options with an exercise price of $2.32, aligning executive incentives with shareholder interests.
Adverum Biotechnologies, Inc. director C. David Nicholson was granted 10,450 stock options with an exercise price of $2.32, vesting on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.
Adverum Biotechnologies, Inc. Director Patrick Machado was granted stock options to purchase 13,590 shares of common stock at an exercise price of $2.32 per share, vesting in 2026.
Peter Soparkar, Chief Operating Officer of Adverum Biotechnologies, sold shares of common stock on May 15, 2025, to satisfy tax obligations related to vesting performance stock units.
Setareh Seyedkazemi, Chief Development Officer of Adverum Biotechnologies, sold 924 shares of common stock to satisfy tax obligations related to vesting performance stock units.
CEO Laurent Fischer sold 9,126 shares of Adverum Biotechnologies stock to satisfy tax obligations related to vesting and settlement of performance stock units.
4/A: Adverum Biotechnologies Insider Leonard Braden Michael Amends Filing to Correct Transaction Details
Leonard Braden Michael, a director and 10% owner of Adverum Biotechnologies, amended a previous filing to correct a clerical error regarding a transaction on March 27, 2025, and to clarify the form type.
Director Braden Michael Leonard reports purchasing additional shares of Adverum Biotechnologies, Inc., increasing his direct and indirect holdings.
Director Braden Michael Leonard reports purchasing additional shares of Adverum Biotechnologies, Inc. (ADVM) on April 22nd and 23rd, 2025.
Director Braden Michael Leonard increases his indirect holdings in Adverum Biotechnologies through purchases made by BML Investment Partners, L.P.
Director Braden Michael Leonard reports purchasing additional shares of Adverum Biotechnologies, Inc. on March 26th and 27th, 2025.
Director Braden Michael Leonard reports purchasing additional shares of Adverum Biotechnologies, Inc. through BML Investment Partners, L.P.
Director Braden Michael Leonard, through BML Investment Partners, L.P., has increased his indirect holdings in Adverum Biotechnologies, Inc. (ADVM) via a series of open market purchases.
Form 4: Adverum Biotechnologies' Chief Medical Officer Receives Stock Options and Restricted Stock Units
Rabia Gurses Ozden, Chief Medical Officer of Adverum Biotechnologies, reports acquisition of stock options and restricted stock units.
Setareh Seyedkazemi, Chief Development Officer of Adverum Biotechnologies, reports acquisition of shares and stock options.
CEO Laurent Fischer reports acquisition of shares and stock options in Adverum Biotechnologies.
Form 4: Adverum Biotechnologies CFO Linda Rubinstein Reports Acquisition of Shares and Stock Options
Linda Rubinstein, CFO of Adverum Biotechnologies, reports the acquisition of common stock and stock options, as well as holdings following reported transactions.
Peter Soparkar, Chief Operating Officer of Adverum Biotechnologies, reports acquisition of shares and stock options.
Rabia Gurses Ozden, Chief Medical Officer of Adverum Biotechnologies, acquired 44,010 stock options on August 2, 2024.
Linda Rubinstein, CFO of Adverum Biotechnologies, acquired stock options for 62,083 shares of common stock on August 2, 2024.
Setareh Seyedkazemi, Chief Development Officer of Adverum Biotechnologies, acquired 43,458 stock options on August 2, 2024.
Peter Soparkar, Chief Operating Officer of Adverum Biotechnologies, acquired 64,394 stock options on August 2, 2024, according to a Form 4 filing with the SEC.
CEO Laurent Fischer received stock options for 200,000 shares of Adverum Biotechnologies stock on August 2, 2024.
Braden Michael Leonard, a director and 10% owner of Adverum Biotechnologies, acquired 85,800 shares of common stock at $7.15 per share on July 30, 2024.
Director Leonard Braden Michael reports purchasing additional shares of Adverum Biotechnologies through BML Investment Partners, L.P.
Rabia Gurses Ozden, Chief Medical Officer of Adverum Biotechnologies, was granted stock options to purchase 85,000 shares of common stock on June 17, 2024.
C. David Nicholson, a director of Adverum Biotechnologies, acquired stock options exercisable for 10,520 shares of common stock on June 17, 2024.
Director Soo Hong acquired 10,520 stock options in Adverum Biotechnologies on June 17, 2024, according to a Form 4 filing.
Mark L. Lupher, Jr., a director of Adverum Biotechnologies, acquired stock options exercisable for 10,520 shares of common stock.
Director Dawn Svoronos reports the grant of stock options in Adverum Biotechnologies.